Pharmacological USP2 targeting suppresses ovarian cancer growth by potentiating apoptosis and ferroptosis
Authors:
- 31 October 2024
- journal article
- research article
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 762, 110193
Abstract
No abstract availableKeywords
Funding Information
- Scientific Research Fund of Liaoning Provincial Education Department (LJKZ0829)
- China Postdoctoral Science Foundation (2020M680921)
- Department of Education of Liaoning Province
- National Natural Science Foundation of China (82103146)
This publication has 34 references indexed in Scilit:
- Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancerGeroScience, 2023
- Deubiquitinating enzymes: Promising targets for drug resistanceDrug Discovery Today, 2022
- Appropriate Selection of PARP Inhibitors in Ovarian CancerCurrent Treatment Options in Oncology, 2022
- The intricacies of NRF2 regulation in cancerSeminars in Cancer Biology, 2021
- Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistanceExperimental & Molecular Medicine, 2021
- Deubiquitylases in developmental ubiquitin signaling and congenital diseasesCell Death & Differentiation, 2020
- Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?Archives of Gynecology and Obstetrics, 2020
- Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma2020
- Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistanceDrug Resistance Updates, 2020
- JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1Cell Death & Differentiation, 2019